![5000100-flag[1].jpg](https://cdn.european-virus-archive.com/sites/default/files/5000100-flag%5B1%5D.jpg)
The best way to get viral material within the Scientific Community. Browse our viruses and derived products from the EVAg Portal.
A unique biological resource in the field of virology, readily available online. Users may benefit from special funding to access to products of interest, do not hesitate to apply.
An international group of 25 laboratories, including 16 EU member state institutions and 9 non-EU institutions, that represent an extensive range of virological disciplines.
An open entity aiming at developing synergies and complementary capabilities in such a way as to offer an improved access to researchers.
The quality of viruses and derived products is a key consideration when our products are to be made available. Improvements on quality process will be addressed during the project.
EVAg generates and distributes globally diagnostic materials and protocols in the event of epidemiological emergencies.
Focused on the creation of new tools, techniques and concepts to develop the infrastructure and to provide easier and less expensive access to virological materials.
A user-friendly web Portal with a continuously increasing number of viruses and derived products. Start here...
The EVAg initiative will increase competitiveness and, provides for a strong interaction with industry and a promising foundation for the innovation process between academia and industry.
- The European Commission -
The initiative has an important social impact with particular emphasis on human disease.
- The European Commission -
The quality of the installations cooperating in this consortium is excellent, representing some of the best available infrastructures across the EU and world-wide.
- The European Commission -
***IMPORTANT*** The UK variant of SARS-CoV-2 will be available on the EVA catalogue for orders, probably begining of January 2021. Made available by EVA partners @PHE_uk #SARSCoV2 #UKvariant https://t.co/KsYZvDcKFt
New milestone achieved for EVA: the first 🍇🫒🌴PLANT VIRUS product was added today by our partners at the Biomedical Research Center of the Slovak Academy of Science😃 ! Many more to come soon, stay tuned ! @PlantpathDog @Euphresco @Be_Phytopath @HeikoZiebell @Blisteredcanker https://t.co/ZXkzYQg1f8
Our latest paper is out: presenting the importance of biobanking as a preparedness tool against viral emergence. #Biobanking #COVID19 @BBMRIERIC @ISBER_ORG @IreneNorstedt @EU_H2020 @univamu @SFV_France @ESCVirology @WSVirology @AmerSocVirol https://t.co/ygqaOcztZ7
@francescoflo @LastWeekTonight @Snowden @iamjohnoliver Yes, Biobanking can not afford bad press !
@francescoflo I have to say, this is very well organised ! Thank you
This week we are attending the #EBW20 meeting. Covering today the topic of Global epidemic prevention strategies and the role of pathogen archives. @BiobankWeek @BBMRIERIC @ESBBNews
This section is dedicated to preclinical evaluation of molecules with antiviral potential against the SARS-CoV-2. It may receive links to important pu... read more
The EVA-GLOBAL community supports fair and equitable benefit sharing as conceived in various United Nations frameworks. The consortium is actively imp... read more
Our lab detected first coastal Kenya COVID-19 positive cases using EVA primers. This has allowed aggressive contact tracing and case isolation. Now were are key contributors in diagnostics in the Kenya and obtaining more diagnostic kits will go a long way in supporting local and national COVID-19 response plan.
Thank you so much! The package already arrived - I am amazed. We have so much problems with the primers and probes - some did not work, some were contaminated. Your ones are the only ones which work perfectly in our hands now. With your delivery, we can go on and meanwhile try to test additional providers.
We at Luminex were sincerely appreciative of your willingness to work with us during the development of our xMAP® MultiFLEX™ Zika RNA Assay. The materials from EVAg supported our FDA submission, which is now authorized for emergency use.
Sarah M. Dunlap, PhDDirector, Clinical Operations - Luminex Corporation
We received high quality products at no cost. It helped us a lot in achieving our project. Thank you!
John UserR & D - Laboratory
